HMGCS1: A Potential Drug Target and Biomarker (G3157)

Target Name: HMGCS1

NCBI ID: G3157

HMGCS1

HMGCS1: A Potential Drug Target and Biomarker

HMGCS1, also known as 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble), is a protein that plays a crucial role in the synthesis of a key enzyme in the body known as HMG-CoA reductase. This enzyme is responsible for converting HMG-CoA, a byproduct of the 3-beta-hydroxysteroid dehydrogenase (3-beta-HSD) enzyme, into 3-beta-hydroxysteroid, which is then excreted from the body.

HMGCS1 is a enzyme that is expressed in many different tissues throughout the body, including the liver, heart, and kidneys. It is primarily localized to the liver, where it is involved in the metabolism of a variety of compounds, including drugs such as statins, which are used to treat conditions such as heart disease and diabetes.

One of the key functions of HMGCS1 is its role in the synthesis of HMG-CoA, which is a key precursor to the synthesis of many different compounds, including steroids, sex hormones, and other drugs. HMG-CoA is also a precursor to the synthesis of coenzyme A, which is involved in the metabolism of a wide range of compounds, including energy metabolism and cellular signaling.

In addition to its role in the synthesis of HMG-CoA, HMGCS1 is also involved in the regulation of the activity of other enzymes. For example, it has been shown to play a role in the regulation of the activity of the enzyme HMG-CoA reductase, which is responsible for converting HMG-CoA into 3-beta-hydroxysteroid.

The role of HMGCS1 in the synthesis of HMG-CoA and its regulation of other enzymes makes it an attractive target for drug development. Many drugs that are used to treat diseases are designed to inhibit the activity of HMGCS1, with the goal of reducing the production of unwanted side effects or the production of harmful compounds.

In addition to its potential as a drug target, HMGCS1 is also a potential biomarker for a variety of diseases. For example, high levels of HMGCS1 expression have been observed in a variety of diseases, including heart disease, diabetes, and cancer. Additionally, changes in the levels of HMGCS1 have been observed as a response to certain medications, which suggests that they may be useful as biomarkers for monitoring the effectiveness of these drugs.

Overall, HMGCS1 is a protein that plays a crucial role in the synthesis of key enzymes in the body, and is an attractive target for drug development. Its role in the synthesis of HMG-CoA and its regulation of other enzymes makes it an important player in a variety of biological processes, and its potential as a biomarker for a variety of diseases makes it an important tool for the development of new treatments.

Protein Name: 3-hydroxy-3-methylglutaryl-CoA Synthase 1

Functions: Catalyzes the condensation of acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, which is converted by HMG-CoA reductase (HMGCR) into mevalonate, a precursor for cholesterol synthesis

The "HMGCS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGCS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets